amivantamab
amivantamab: 23 clinical trials tracked.
amivantamab evidence translation
What we can confirm
23 tracked trials
What it means
What to watch
Prepared research question
What is verified about amivantamab, and what remains unknown?
Traceable citations · Unknowns marked
See linked entities and source evidence3 indications · 4 study sponsors
Clinical Trials (23)showing 10 most recent
A Phase 2 Study Evaluating the Safety and Efficacy of Neoadjuvant Amivantamab in Combination With Lazertinib or Chemotherapy in Resectable EGFR-Mutated Non-Small Cell Lung Cancer
Primary endpoint: Major Pathologic response (MPR)
A Phase 1/2 Study Evaluating the Safety and Efficacy of Amivantamab and Olomorasib Combination Therapy in Metastatic Non-small Cell Lung Cancer
Primary endpoint: Phase 1: Number of Participants with Adverse Events (AEs) by Severity
A Phase 3, Randomized, Open-Label, Multicenter Study of Amivantamab in Addition to Carboplatin and Pembrolizumab, Compared to Standard of Care Platinum and Pembrolizumab and 5-FU, in Participants With Treatment-Naïve Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Primary endpoint: Overall Survival (OS)
Phase II Trial of Amivantamab Plus Monochemotherapy in Platinum Unfit NSCLC Patients With EGFR exon20 Insertion Mutations.
Primary endpoint: ORR
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination With Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination With Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Primary endpoint: Progression Free Survival (PFS)
A Randomized, Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Recurrent, Unresectable or Metastatic Colorectal Cancer Who Have Received Prior Chemotherapy
Primary endpoint: Progression-Free Survival (PFS) as Assessed by Blinded Independent Central Review (BICR)
A Phase II Study of Amivantamab SC (Subcutaneous) in Participants With MET Amplification-Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP SUB-STUDY)
Primary endpoint: Response rate for amivantamab-subcutaneous
A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
Primary endpoint: Progression-Free Survival (PFS) as Assessed by Blinded Independent Central Review (BICR)
5G-EMERALD: A Phase 1 Trial of Amivantamab in High Grade Malignant Brain Tumours Within the 5G Platform
Primary endpoint: Phase 1b - To evaluate the safety and tolerability of investigational agent in patients with malignant brain tumours
61186372PANSC2003: 61186372PANSC2003 ISA#3 Platform Trial
Primary endpoint: Phase 1: Number of Participants with Adverse events (AEs) by Severity